Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.
- First Posted Date
- 2011-01-14
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01276990
Bioequivalence of a Fixed Dose Combination Tablet Linagliptin/Pioglitazone Compared With Its Mono-components
- Conditions
- Healthy
- Interventions
- Drug: Linagliptin/Pioglitazone
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT01276327
- Locations
- 🇩🇪
1264.14.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
DDI Between BI Empagliflozin (10773) and Verapamil
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01276301
- Locations
- 🇩🇪
1245.43.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 23
- Registration Number
- NCT01276288
- Locations
- 🇩🇪
1245.42.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT01271725
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇮🇳Curie Manavata Cancer Centre, Maharashtra, India
🇷🇺St.Auton.Heal.Inst."Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan", Kazan, Russian Federation
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 398
- Registration Number
- NCT01257230
- Locations
- 🇺🇸
205.444.01005 Boehringer Ingelheim Investigational Site, Columbia, Missouri, United States
🇺🇦205.444.38004 Boehringer Ingelheim Investigational Site, Kiev, Ukraine
🇺🇦205.444.38010 Boehringer Ingelheim Investigational Site, Zaporizhya, Ukraine
A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 94
- Registration Number
- NCT01251653
- Locations
- 🇫🇷
1200.93.33002 Boehringer Ingelheim Investigational Site, Dijon, France
🇫🇷1200.93.33001 Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France
🇫🇷1200.93.33003 Boehringer Ingelheim Investigational Site, Toulouse, France
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 91
- Registration Number
- NCT01248364
- Locations
- 🇩🇪
1245.39.49002 Boehringer Ingelheim Investigational Site, Neuss, Germany
🇦🇹1245.39.43001 Boehringer Ingelheim Investigational Site, Graz, Austria
🇮🇹1245.39.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy
A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 674
- Registration Number
- NCT01243268
- Locations
- 🇰🇷
NISND Center, One Or Multiple Sites, Korea, Republic of
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6103
- Registration Number
- NCT01243424
- Locations
- 🇺🇸
PMI Health Research Group, Atlanta, Georgia, United States
🇺🇸North Alabama Research Center, LLC, Athens, Alabama, United States
🇺🇸Matrix Research Institute, Tustin, California, United States